Dividend Power Score
A single, comprehensive score designed to measure the true strength of a company’s dividend.
This score combines three essential pillars of dividend quality:
Consistency – Measures how reliable the dividend has been over time, focusing on payment history, stability, and the absence of cuts or suspensions.
Payability – Assesses the company’s financial ability to sustain its dividend, taking into account cash flow, earnings coverage, balance sheet strength, and overall financial health.
Growth – Evaluates the long-term growth of both the dividend and the company’s share price, highlighting businesses that consistently increase payouts while creating shareholder value.
Higher scores identify companies that have historically delivered dependable income alongside sustained dividend growth and long-term capital appreciation.
Company Overview
BICO Group AB (publ) is a Sweden-based life science technology company that develops, manufactures, and sells advanced tools and technologies for biomedical research, drug discovery, and cell-based applications. The company operates primarily within the life science tools and services industry, with a focus on enabling the transition from traditional laboratory workflows to more automated, scalable, and reproducible systems. Its offerings are used by academic research institutions, biotechnology and pharmaceutical companies, and industrial laboratories.
The company’s core revenue drivers are centered on bioprinting systems, laboratory automation, consumables, and specialized instruments for cell biology and drug discovery. BICO Group AB was founded in 2016 under the name Cellink AB, initially focused on 3D bioprinting technologies. Through a series of acquisitions and internal expansion, the company broadened its scope beyond bioprinting and rebranded as BICO Group AB in 2021 to reflect its diversified portfolio across multiple life science verticals.
Business Operations
BICO Group AB operates through multiple business units that collectively support research workflows from early discovery through preclinical development. Its main business segments include Bioprinting, Biosciences, Lab Automation, and Bioautomation, generating revenue through the sale of instruments, recurring consumables, software, and services. The company controls proprietary technologies related to 3D bioprinting, cell handling, imaging, and automated laboratory processes.
Operations are conducted across both domestic and international markets, with manufacturing, R&D, and commercial activities spanning Europe, North America, and Asia. BICO Group AB owns several subsidiaries acquired over time, including CELLINK, Cytena, Scienion, Disptec, Nanoscribe, and MatTek, which operate with a degree of autonomy while contributing to the group’s integrated product ecosystem. These subsidiaries enable cross-selling and bundled solutions across customer segments.
Strategic Position & Investments
The company’s strategic direction emphasizes long-term growth through technology integration, recurring revenue expansion, and selective acquisitions that complement its automation and life science platforms. BICO Group AB has invested heavily in expanding its portfolio through acquisitions such as MatTek Corporation, which strengthened its position in 3D cell models and tissue-based assays, and Nanoscribe, which added high-precision micro- and nanoscale 3D printing capabilities.
Strategically, the company is focused on emerging areas such as advanced cell models, organ-on-a-chip systems, and automated drug discovery workflows. These investments position BICO Group AB to benefit from increasing demand for more predictive preclinical models and reproducible laboratory processes, particularly within pharmaceutical and biotechnology research environments.
Geographic Footprint
BICO Group AB is headquartered in Gothenburg, Sweden, and maintains a significant operational presence across Europe, North America, and Asia-Pacific. The company derives a substantial portion of its revenue from international markets, with the United States representing one of its largest end markets due to strong demand from academic and commercial life science customers.
Through its subsidiaries, the company operates manufacturing facilities, R&D centers, and sales offices in countries including Sweden, Germany, France, Switzerland, the United States, and Japan. This global footprint supports localized customer engagement while allowing centralized development of core technologies and platforms.
Leadership & Governance
BICO Group AB is led by an executive team with backgrounds in life sciences, engineering, and international business development. The leadership philosophy emphasizes innovation, decentralization across subsidiaries, and long-term value creation through scientific advancement rather than short-term financial optimization.
Key executives include:
- Erik Gatenholm – Co-Founder and Chief Executive Officer
- Hugo Geiger – Chief Financial Officer
- Markus Wåhlander – Chief Operating Officer
- Helena Jansson – Chief Human Resources Officer
- Therese Sjögren – Chief Communications Officer
The company is publicly listed on Nasdaq Stockholm and governed by a board of directors responsible for oversight, risk management, and alignment with shareholder interests, in accordance with Swedish corporate governance standards.